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Background: Fibulin-5 has been considered as a tumor suppressor through inhibiting tumor growth and invasion.
Reduced expression of Fibulin-5 is frequently observed in various human cancers. In this study, we investigate the
clinical significance of Fibulin-5 and its role in hepatocellular carcinoma (HCC) cell migration and invasion.
Methods: The expression of Fibulin-5 was evaluated by qRT-PCR and immunoblotting in HCC and matched
noncancerous tissues. Fibulin-5 was over-expressed or knocked down by a retrovirus-mediated expression plasmid
or a specific siRNA in HCC cells. Boyden chamber and Transwell assays were used to test HCC cell migration and
invasion. Immunostaining was performed to determine matrix metalloproteinase-7 (MMP-7) expression in HCC
specimens. MMP-7 retroviruses and siRNA were used to alter MMP-7 expression in HCC cells.
Results: In our study, the expression levels of Fibulin-5 protein and mRNA were down-regulated in HCC tissues
as compared with those in matched noncancerous tissues. Reduced expression of Fibulin-5 was observed in all
HCC cell lines (HepG2, SMMC-7721, MHCC97L, Hep3B, MHCC97H and HCC-LM3) as compare with that in a
non-transformed hepatic cell line (LO2). Low expression of Fibulin-5 was significantly correlated with poor prognostic
features including multiple tumor nodes, venous infiltration, high Edmondson-Steiner grading and advanced tumor-
node-metastasis (TNM) tumor stage. Furthermore, we demonstrated that Fibulin-5 was a novel independent prognostic
marker for predicting 5-year survival of HCC patients. Our in vitro studies showed that Fibulin-5 overexpression inhibited
HCC cell migration and invasion. While Fibulin-5 knockdown increased the number of migrated and invaded HCC cells.
Fibulin-5 negatively regulated MMP-7 abundance in HCC cells. Moreover, the inverse correlation between Fibulin-5 and
MMP-7 expressions was observed in HCC tissues. Mechanistically, we disclosed that MMP-7 knockdown reduced the
number of migrated and invaded HCC cells. Restoring MMP-7 expression abrogated the suppressive effect of Fibulin-5
on HCC cell migration and invasion in vitro, suggesting that Fibulin-5 exerted its anti-metastatic function, at least in part,
by down-regulating the expression of MMP-7 in HCC cells.
Conclusions: These results indicate that Fibulin-5 may serve as a prognostic biomarker and inhibits HCC invasion and
metastasis by suppressing MMP-7 expression.
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Fibulin-5 is a member of Fibulin family, which are charac-
terized by calcium-binding epidermal growth factor (EGF)-
like repeats and a globular carboxyl-terminal Fibulin type
structure [1,2]. Distinct from other members, Fibulin-5
contains an integrin-binding RGD motif which binds to* Correspondence: tks0912@foxmail.com; liuqingguang@vip.sina.com
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Functionally, Fibulin-5 is involved in cell-to-cell and cell-
to-matrix communication; it also regulates the extra-
cellular matrix structure and functions in fibrogenesis,
angiogenesis and tumorigenesis [5-7].
Fibulin-5 expression was down-regulated in the malig-
nancies of kidney [8], breast [9], ovary [9], colon [9],
prostate [10], bladder [11] and lung [12]. In vitro studies
showed Fibulin-5 inhibited proliferation and invasion ofis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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promoted tumor growth partly through suppressing
Fibulin-5 expression [13]. Fibulin-5 has also been impli-
cated in inhibiting lung cancer metastasis by modulating
matrix metalloproteinase7 (MMP7) expression [12].
These studies indicate that Fibulin-5 probably functions
as a suppressor for tumor formation and metastasis.
However, other studies showed the pro-tumor role of
Fibulin-5. Fibulin-5 was found to enhance the malig-
nancy of human fibrosacroma cells [9]. Fibulin-5 expres-
sion was found to be stimulated by transforming growth
factor (TGF)-beta in mammary epithelial cells (MECs)
and its upregulation resulted in MEC invasion and
epithelial-mesenchymal transition (EMT) via a MMP-
dependent mechanism [14]. Oncogenic Fibulin-5 pro-
motes nasopharyngeal carcinoma cell metastasis correlates
with poor prognosis [15]. In Hela cells that overexpress
Nogo-B, cell migration and invasion was promoted by the
elevated secretion of Fibulin-5 [16]. Therefore, the precise
function of Fibulin-5 in tumorigenesis and metastasis var-
ies between different cancer types. However, Fibulin-5 in
the initiation and progression of HCC remains poorly
understood.
In this study, we find that Fibulin5 expression is im-
paired in HCC. Clinical analysis indicates that Fibulin-5
has a prognostic role in predicting survival of HCC pa-
tients. Fibulin-5 inhibits cell migration and invasion and
inversely regulates MMP-7 abundance in HCC cells. Im-
portantly, the anti-metastatic effect of Fibulin-5 is inverted
by restoring MMP-7 expression in vitro. Our results
suggest that Fibulin-5 may inhibit MMP-7 expression,




86 HCC samples were collected from patients including
69 males and 17 females, who underwent the resection
of their primary HCC in the Department of Hepatobiliary
Surgery at the First Affiliated Hospital of Xi’an Jiaotong
University during January 2006 to December 2008. Patients
did not receive preoperative chemotherapy or embolization.
All samples were used after obtaining informed consent.
The demographic features and clinicopathologic date are
shown in Table 1. The Xi’an Jiaotong University Ethics
Committee approved all protocols according to the Declar-
ation of Helsinki (as revised in Tokyo 2004).
Western blot
Fibulin-5 (R&D system, Minneapolis, MN, USA) and
MMP-7 (EMD BioSciences, San Diego, CA, USA) and
GAPDH (G8140, US Biological, Salem, MA, USA) anti-
bodies were used for immunoblotting assay as previously
described [17].Real-time quantitative reverse transcription polymerase
chain reaction (qRT-PCR)
Fibulin-5 primers (forward: 5′-TCGCTATGGTTACTGC-
CAGCA-3′; reverse: 5′-TTGGCAAGACCTTCCATCGT
C-3′). The PCR amplification for the quantification of the
Fibulin-5 mRNA and the GAPDH mRNA was performed
using a SYBR® Premix Ex Taq™ ii (Perfect Real Time) Kit
(Takara Bio, Shiga, Japan), as previously described [18].
Immunohistochemical staining
Immunohistochemistry was performed with mouse anti-
bodies against Fibulin-5 (R&D system) and MMP-7 (EMD
BioSciences) as previously described [19]. The percentage
of positive tumor cells was graded as per the following
criteria: 0, less than 10%; 1, 10–30%; 2, 31–50%; 3, more
than 50%.
Cell lines and transfection
The human immortalized normal hepatocyte cell line,
LO2, and six HCC cell lines, HepG2, MHCC97L,
Hep3B, SMMC-7721, MHCC97H and HCC-LM3 (the
Institute of Biochemistry and Cell Biology, Chinese
Academy of Sciences, Shanghai, China), were cultured in
complete Dulbecco’s modified Eagle medium (DMEM,
Gibco, Grand Island, NY, USA) containing 10% fetal bo-
vine serum (FBS, Gibco) with 100 units/mL penicillin
and 100 μg/mL streptomycin (Sigma, St-Louis, MO,
USA) in a humidified containing of 5% CO2 incubator
at 37°C.
Retroviral vectors pMMP-Fibulin-5 and pMMP-MMP-
7 were generated by inserting the cDNA into pMMP.
Retrovirus packaging and transduction were described
previously [20]. Fibulin-5 was knocked down using a
small interfering RNA (siRNA) duplexes (ON-TARGET-
plus siRNA J-017621-05 and −06; GE Dharmacon, Chi-
cago, IL, USA). MMP-7 was knocked down by MMP-7
757 (GGCAUUCAGAAACUAUAUG) and MMP-7 877
(GCACUGUUCCUCCACUCCA) (GE Dharmacon) [12].
Cells were transfected with the siRNAs mentioned above
using Lipofectamine 2000 according to the manufac-
turer’s instructions (Invitrogen, Carlsbad, CA, USA).
Boyden chamber and Transwell assays
A Boyden chamber assay (NeuroProbe, Gaithersburg, MD,
USA) was used to analyze HCC cell migration as previously
described [21]. Transwell assays were done in 6 well plates
with Transwell inserts equipped with 8-μm pores (Nalge
Nunc International Corp, Naperville, IL, USA) coated with
Matrigel at 1:6 dilution (Becton Dickinson Labware, Bed-
ford, MA, USA) as previously described [22].
Statistical analysis
Results are expressed as Mean ± SEM. Significance was
established, with the SPSS statistical package for Windows
Table 1 Clinical correlation of Fibulin-5 expression in HCC
Clinicopathologic features Total No. of
patients, n = 86
No. of patients P
Fibulin-5low Fibulin-5high
Age (y) <50 27 15 12 0.208
≥50 59 41 18
Sex Male 69 44 25 0.597
Female 17 12 5
HBV Absent 30 19 11 0.800
Present 56 37 19
Serum AFP level (ng/mL) <400 34 24 10 0.389
≥400 52 32 20
Tumor size (cm) <5 30 22 8 0.242
≥5 56 34 22
No. of tumor nodules 1 66 49 17 0.001*
≥2 20 7 13
Cirrhosis Absent 37 26 11 0.384
Present 49 30 19
Venous infiltration Absent 42 33 9 0.011*
Present 44 23 21
Edmondson-Steiner grading I + II 29 24 5 0.014*
III + IV 57 32 25
TNM tumor stage I + II 61 44 17 0.033*
III + IV 25 12 13
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; AFP, alpha-fetoprotein; TNM, tumor-node-metastasis. *Statistically significant.
Tu et al. BMC Cancer 2014, 14:938 Page 3 of 9
http://www.biomedcentral.com/1471-2407/14/938Version 13 (SPSS, Chicago, IL, USA) and GraphPad Prism
5 software (GraphPad Software, Inc, San Diego, CA,
USA), using a Pearson chi-squared test, the multi-variant
Cox regression analysis, a two-tailed Student’s t test, a
Kaplan–Meier plot, a log-rank test, a Spearman’s rank cor-
relation coefficient or an ANOVA when appropriate. Dif-
ference were considered significant when P < 0.05.
Results
The expression of Fibulin-5 in HCC specimens and cells
Initially, we tested Fibulin-5 expression in a retrospective
cohort of 86 HCC samples using Western blot. In these
cases, we found that Fibulin-5 expression in HCC tissues
was prominently lower than that in matched tumor-
adjacent tissues (P < 0.05, Figure 1A). 20 pairs of tumor
tissues and matched adjacent nontumor tissues were
subjected to qRT-PCR for Fibulin-5 mRNA. The differ-
ence of Fibulin-5 mRNA levels between cancer and non-
cancerous tissues were the same as protein levels (tumor:
0.92 ± 0.10 vs nontumor: 1.93 ± 0.12, P < 0.05). Further-
more, Fibulin-5 mRNA levels were down-regulated in
HCC cell lines, Hep3B, HepG2, MHCC97L, SMMC-7721,
MHCC97H and HCC-LM3, as compared with that in nor-
mal hepatocyte cell line, LO2 (P < 0.05, Figure 1B). More-
over, Fibulin-5 expression in the highly metastatic HCCcell lines, MHCC97H and HCC-LM3, were obviously
lower than those in the low metastatic HCC cell lines
including HepG2, MHCC97L, SMMC-7721 and Hep3B
(P < 0.05, Figure 1B). As determined by Western blot, the
levels of Fibulin-5 protein showed the same pattern as
mRNA levels in all cell lines (Figure 1B). Thus, our data
indicate that Fibulin-5 is down-regulated in HCC tissues
and cells.
Clinical significance of Fibulin-5 expression in HCC
We determined 0.31 as a cutoff value, which was defined
as the mean of the cohort, for Fibulin-5 protein level.
Fibulin-5 expression was considered as either low (<0.31,
n = 56) or high (≥0.31, n = 30). As shown in Table 1, low
expression of Fibulin-5 protein was prominently asso-
ciated with multiple tumor nodes (P = 0.001), venous
infiltration (P = 0.011), high Edmondson-Steiner grading
(P = 0.014) and advanced tumor-node-metastasis (TNM)
tumor stage (P = 0.033). Thus, our results indicate that the
reduced expression of Fibulin-5 is correlated with poor
prognostic features of HCC. Next, 86 HCC patients with
clinical survival information (with a median follow-up
time of 35.5 months) were analyzed by Kaplan Meier esti-
mation. Tumors with high expression of Fibulin-5 indeed
associated with better overall survival and disease-free
Figure 1 Expression of Fibulin-5 in HCC. A) Representative Western blot analysis of Fibulin-5 expression in the HCC (T) and matched adjacent
nontumor tissues (NT) was shown. Quantification of the data revealed that Fibulin-5 protein expression level in the cancer tissues was significantly
lower than that in the noncancerous tissues. n = 86; *P < 0.05 by t test. B) Comparing differences in the expression levels of Fibulin-5 between HCC cell
lines with different metastatic potentials and the immortalized hepatic cell line LO2. n = three repeats with similar results; *P < 0.05 by ANOVA.
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Furthermore, Fibulin-5 expression was an independent
factor for predicting both 5-year overall and disease-free
survival in HCC patients (P = 0.005 and 0.001, respect-
ively, Table 2). These data indicate that Fibulin-5 may act
as a potent biomarker for predicting prognosis of HCC
patients.
Fibulin-5 inhibits HCC cell migration and invasion
We transduced HCC cell line, HCC-LM3, with empty
vector (EV) or Fibulin-5 retroviruses. As measured by
Western blot, the level of Fibulin-5 protein was signifi-
cantly up-regulated by ectopically expressing Fibulin-5 in
HCC-LM3 cells (P < 0.05, Figure 3A). Boyden chamber as-
says were performed to test the effect of altering Fibulin-5Figure 2 Prognostic significance of Fibulin-5 in HCC cases. Kaplan-Mei
according to the level of Fibulin-5 protein expression. The Fibulin-5 high ex
n = 56). The mean expression value obtained for Fibulin-5 of the 86 HCC sa
*P < 0.05 by log-rank test.levels on HCC cell migration. We found that Fibulin-5
overexpression led to a significant reduction of cell migra-
tion in HCC-LM3 cells (P < 0.05, Figure 3B). Furthermore,
as determined by Transwell assays, the number of invaded
HCC-LM3 cells was significantly reduced after Fibulin-5
overexpression (P < 0.05, Figure 3B). Next, Fibulin-5 was
knocked down by a specific siRNA in MHCC97L cells
(P < 0.05, Figure 3C). As expected, Fibulin-5 knockdown
obviously promoted HCC cell migration and invasion
(P < 0.05, respectively, Figure 3D). However, Fibulin-5
overexpression did not significantly affect cell growth (EV:
102.20 ± 3.36 vs Fibulin-5: 95.00 ± 3.10, P = 0.148) and
apoptosis (EV: %11.17 ± 1.08 vs Fibulin-5: %13.25 ± 1.05,
P = 0.196) in HCC-LM3 cells. Thus, Fibulin-5 may exert
an anti-metastatic effect on HCC.er 5-year A) overall and B) disease-free survival curves of HCC patients
pression group (>0.31, n = 30); Fibulin-5 low expression group (<0.31,
mples detected by Western blot was chosen as the cutoff value.
Table 2 Multivariate Cox regression analysis of 5-year overall and disease-free survival of 86 HCC patients
Variables Overall survival Disease-free survival
HR 95% CI P HR 95% CI P
No. of tumor nodules 1.701 0.666-4.342 0.267 1.064 0.209-5.421 0.940
Venous infiltration 1.054 0.999-1.112 0.056 1.067 0.504-2.260 0.865
Edmondson-Steiner grading 2.230 0.937-5.308 0.070 1.971 0.827-4.696 0.126
TNM tumor stage 1.023 1.002-1.044 0.032* 1.055 1.019-1.092 0.003*
Fibulin-5 expression in tumor 2.148 1.255-3.677 0.005* 3.547 1.644-7.653 0.001*
TNM, tumor-node-metastasis; HR, hazard ratio; CI, confidence interval. *Statistically significant.
Figure 3 Fibulin-5 reduces HCC cell migration and invasion. A) HCC-LM3 cells that were transfected with empty vector (EV) or Fibulin-5
retroviruses were subjected to western blot for Fibulin-5. n = six independent experiments; *P < 0.05 by t test. B) Cell migration and invasion as
measured by Boyden chamber and Transwell assays were inhibited by Fibulin-5 overexpression in HCC-LM3 cells as compared with control cells.
n = three repeats with similar results, *P < 0.05 by t test. HPF: high power field. C) MHCC97L cells that were transfected with scrambled siRNA or
Fibulin-5 siRNA were subjected to western blot for Fibulin-5. n = six independent experiments; *P < 0.05 by t test. D) Fibulin-5 knockdown MHCC97L
cells conferred a less number of migrated and invaded cells as compared with control cells. n = three repeats with similar results; *P < 0.05 by t test.
HPF: high power field.
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The inverse correlation between Fibulin-5 and MMP-7
expression was reported previously in lung cancer [12].
HCC-LM3 cells that were transfected with EV or
Fibulin-5 were subjected to immunoblotting for MMP-7
protein. Interestingly, we found that Fibulin-5 overex-
pression significantly decreased the level of MMP-7 protein
(P < 0.05, Figure 4A). Furthermore, Fibulin-5 knockdown
obviously increased the level of MMP-7 protein in
MHCC97L cells (P < 0.05, Figure 4B). We next detected
Fibulin-5 and MMP-7 expression using immunostaining
in a cohort of 86 HCC samples. Fibulin-5 or MMP-7 im-
munoreactivity was considered as either negative (score 0)
or positive (scores 1 to 3). In these cases, MMP-7 ex-
pression was detected in 48.5% (32/66) of the HCCFigure 4 Fibulin-5 regulates MMP-7 abundance in HCC. A) Fibulin-5 ov
n = six independent experiments; *P < 0.05 by t test. B) Fibulin-5 knockdow
independent experiments; *P < 0.05 by t test. C) In cases of high Fibulin-5 pro
(II) in the same tissue section. In contrast, in the case of low Fibulin-5 protein
100 μm. D) Fibulin-5 and MMP-7 expression in 86 HCC samples analyzed by i
and MMP-7 expression was observed in HCC. P < 0.05 by two-tailed chi-squarsamples with negative Fibulin-5 expression, whereas
only 15.0% (3/20) of the HCC specimens with positive
Fibulin-5 expression showed a positive MMP-7 signal
(P < 0.05, Figure 4C and 4D). Furthermore, Spearman
correlation analysis indicated that Fibulin-5 was in-
versely correlated with MMP7 expression in HCC tis-
sues (r = −0.632, P < 0.001). These data indicate that
Fibulin-5 reduces MMP-7 protein levels in HCC.
Fibulin-5 inhibits HCC cell migration and invasion by
suppressing MMP-7
To determine whether the MMP-7 protein participates
in Fibulin-5 mediated suppression of HCC cell migration
and invasion, MMP-7 expression was obviously knocked
down by a specific siRNA in HCC-LM3 cells (P < 0.05,erexpression decreased the level of MMP-7 protein in HCC-LM3 cells.
n led to accumulation of MMP-7 protein in MHCC97L cells. n = six
tein expression (I), there was no detectable MMP-7 protein expression
expression (III), there was strong MMP-7 protein expression (IV). Scale bar:
mmunohistochemistry. A significant inverse correlation between Fibulin-5
e test.
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significantly inhibited HCC cell migration and invasion
(P < 0.05, respectively). Furthermore, Fibulin-5 overex-
pressing HCC-LM3 cells were subsequently transfected
with EV or MMP-7 retroviruses. Restoring MMP-7
expression in HCC-LM3 cells abolished the effect of ex-
ogenous Fibulin-5 overexpression, leading to a signifi-
cant increase in the number of migrated and invaded
cells (P < 0.05, respectively, Figure 5C and 5D). Taken to-
gether, these data indicate that MMP-7 may function as
a downstream factor in Fibulin-5 mediated suppression
of HCC cell migration and invasionFigure 5 Fibulin-5 exerts anti-metastatic effect by suppressing MMP-7
specific siRNA in HCC-LM3 cells. n = six independent experiments; *P < 0.05
MMP-7 knockdown inhibited migration and invasion of HCC-LM3 cells. n =
expressing HCC-LM3 cells that were transfected with empty vector (EV) or
n = six independent experiments; *P < 0.05 by t test. D) Restoring MMP-7 e
HCC-LM3 cells. n = three repeats with similar results, *P < 0.05 by t test.Discussion
In our study, we initially detected Fibulin-5 expression
status in 86 samples of surgical resected HCC tissues.
Our data indicated that the level of Fibulin-5 expression
in HCC was significantly lower than that in normal
tumor-adjacent tissues. Reduced expression levels of
Fibulin-5 mRNA were observed in HCC cell lines, espe-
cially in the highly metastatic cell lines. Furthermore,
Fibulin-5 protein was expressed at significantly lower
levels in HCC patients with multiple tumor nodes, ven-
ous infiltration, high Edmondson-Steiner grading and
advanced TNM tumor stage. These results suggest thatexpression. A) The expression of MMP-7 was knocked down by a
by t test. B) Boyden chamber and Transwell assays indicated that
three repeats with similar results, *P < 0.05 by t test. C) Fibulin-5-
MMP-7 retroviruses were subjected to immunoblotting for MMP-7.
xpression increased migration and invasion in Fibulin-5 expressing
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poor prognostic features in HCC. Importantly, our data
demonstrated that high expression of Fibulin-5 was cor-
related with a significant better 5-year survival for HCC
patients. Multivariate Cox repression analysis indicated
that Fibulin-5 was an independent prognostic factor for
predicting survival of HCC patients. Altogether, these re-
sults suggest that Fibulin-5 expression is critical for
prognosis determination in HCC patients.
Several studies have identified Fibulin-5 as a driving
tumor suppressor in human cancers [8-12]. Mechanistic-
ally, Fibulin-5 exerts anti-cancer functions by inhibiting
tumor growth and metastasis [1]. In our study, we found
that Fibulin-5 overexpression significantly reduced the
number of migrated and invaded HCC-LM3 cells and
Fibulin-5 knockdown prominently promoted MHCC97L
cell migration and invasion. However, Fibulin-5 overex-
pression did not obviously affect cell growth and apop-
tosis. These data confirm that Fibulin-5 indeed inhibits
HCC cell migration and invasion, not kills cells or makes
cells sick. The inverse correlation between Fibulin-5 and
MMP-7 expression has been reported previously and
Fibulin-5 suppresses lung cancer invasion by inhibiting
MMP-7 expression [12]. Our in vitro studies demon-
strated that Fibulin-5 overexpression down-regulated
MMP-7 protein in HCC-LM3 cells and Fibulin-5 knock-
down led to MMP-7 protein accumulation in MHCC97L
cells. Moreover, we found that the MMP-7 expression
level in HCC tissues from negative Fibulin-5 expression
group was prominently higher as compared with that in
HCC tissues from positive Fibulin-5 expression group.
Spearman correlation analysis indicated an inverse cor-
relation between Fibulin-5 and MMP7 expression in
HCC tissues. Thus, our results indicate that Fibulin-5 in-
versely regulate MMP-7 abundance in HCC. We further
confirmed that MMP-7 knockdown by a specific siRNA
inhibited HCC-LM3 cell migration and invasion, which
was consistent with previous reports [23]. Furthermore,
the suppression in HCC cell migration and invasion by
Fibulin-5 overexpression could be reverted by restoring
MMP-7 expression. Taken together, these data suggest
that Fibulin-5 suppresses HCC cell migration and inva-
sion by inhibiting MMP-7 expression. In lung cancer,
suppression of MMP-7 expression by Fibulin-5 was medi-
ated by an integrin-binding RGD motif via the extracellu-
lar signal-regulated kinase (ERK) pathway [12]. Therefore,
further investigation is required to confirm the precise
molecular mechanisms between Fibulin-5 and MMP-7 in
HCC.
In conclusion, we find that Fibulin-5 is down-regulated
in HCC and its low expression is related to malignant cli-
nicopathologic characteristics. Moreover, Fibulin-5 ex-
pression is an independent prognostic marker for
predicting 5-year survival of HCC patients. In vitrostudies demonstrate that Fibulin-5 reduces HCC cell
migration and invasion. Mechanistically, we suggest
that Fibulin-5 may inhibit HCC invasion and metastasis
by suppressing MMP-7. Taken together, we consider
that Fibulin-5 may potentially act as a clinical bio-
marker, and may also be a therapeutic target, in HCC.
Conclusions
In summary, this study shows that Fibulin-5 expression is
down-regulated in tumor tissues as compared with
matched adjacent nontumor liver tissues and that the low
expression of Fibulin-5 confers poor prognostic features of
HCC. Furthermore, we find that Fibulin-5 functions as an
independent factor for predicting the 5-year overall sur-
vival and disease-free survival of HCC patients. Functional
studies demonstrate that Fibulin-5 inhibits HCC cell mi-
gration and invasion. Interestingly, our data indicate that
Fibulin-5 inversely regulates the abundance of MMP-7
protein in HCC cells. An inverse correlation between
Fibulin-5 and MMP-7 is observed in HCC tissues. Import-
antly, MMP-7 knockdown suppresses HCC cell migration
and invasion. Restoring MMP-7 can abolish the effect of
Fibulin-5 overexpression on anti-metastasis in HCC, sug-
gesting that Fibulin-5 may function as a metastasis-
suppressor gene by downregulating MMP-7. This study
reveals that Fibulin-5 may be a potential prognostic bio-
marker of HCC. Fibulin-5 may play a critical role in the
invasion and metastasis of HCC.
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